Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
48
QTTB Quote, Financials, Valuation and Earnings
Last price:
$3.38
Seasonality move
:
-16.61%
Day range:
$3.29 - $3.50
52-week range:
$1.35 - $6.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.74x
Volume:
114.7K
Avg. volume:
6.1M
1-year change:
-13.81%
Market cap:
$41.5M
Revenue:
--
EPS (TTM):
-$3.45
Analysts' Opinion
-
Consensus RatingQ32 Bio, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.00, Q32 Bio, Inc. has an estimated upside of 345.1% from its current price of $3.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $3.37.
Fair Value
-
According to the consensus of 2 analysts, Q32 Bio, Inc. has 345.1% upside to fair value with a price target of $15.00 per share.
QTTB vs. S&P 500
-
Over the past 5 trading days, Q32 Bio, Inc. has overperformed the S&P 500 by 4.45% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Q32 Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Q32 Bio, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Q32 Bio, Inc. reported revenues of --.
Earnings Growth
-
Q32 Bio, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Q32 Bio, Inc. reported earnings per share of -$0.60.
Enterprise value:
9.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.24x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$421K
Return On Assets:
-52.64%
Net Income Margin (TTM):
--
Return On Equity:
-634.27%
Return On Invested Capital:
-256.32%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $8.8M | -$14.7M | -- | -- | -- | |
| Gross Profit | $7.8M | -$15.2M | -$421K | -$123K | -$91K | |
| Operating Income | -$56.9M | -$77.4M | -$43.5M | -$18.8M | -$7.6M | |
| EBITDA | -$55.9M | -$76.9M | -$43.1M | -$18.7M | -$7.5M | |
| Diluted EPS | -$87.79 | -$85.60 | -$3.45 | -$1.46 | -$0.60 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $191.8M | $213.2M | $106.6M | $93.9M | $50.8M | |
| Total Assets | $230.8M | $262.7M | $140.1M | $104.5M | $57.8M | |
| Current Liabilities | $18.7M | $25.3M | $25.3M | $14.4M | $11.1M | |
| Total Liabilities | $32.2M | $53.6M | $51.9M | $86.2M | $76.2M | |
| Total Equity | $198.6M | $209.1M | $88.2M | $18.3M | -$18.4M | |
| Total Debt | $13.5M | $28.3M | $26.6M | $18.4M | $16.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.2M | -- | -$38.8M | -$19.5M | -$4.2M | |
| Cash From Investing | $18M | -- | -$2K | $9.9M | -- | |
| Cash From Financing | $362K | -- | -$1.2M | $997K | -$1.6M | |
| Free Cash Flow | -$35.2M | -- | -$38.8M | -$19.6M | -$4.2M | |
QTTB
Sector
Market Cap
$41.5M
$28.1M
Price % of 52-Week High
52.91%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
1.02%
-1.55%
1-Year Price Total Return
-13.81%
-19.36%
Beta (5-Year)
0.134
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.21
200-day SMA
Buy
Level
$2.15
Bollinger Bands (100)
Buy
Level
1.83 - 3.13
Chaikin Money Flow
Buy
Level
113.7K
20-day SMA
Buy
Level
$3.18
Relative Strength Index (RSI14)
Buy
Level
59.83
ADX Line
Buy
Level
37.91
Williams %R
Sell
Level
-16.6667
50-day SMA
Buy
Level
$2.78
MACD (12, 26)
Buy
Level
0.88
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
641.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.7823)
Sell
CA Score
(Annual)
Level (-9.2046)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.9305)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
Stock Forecast FAQ
In the current month, QTTB has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The QTTB average analyst price target in the past 3 months is $15.00.
-
Where Will Q32 Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Q32 Bio, Inc. share price will rise to $15.00 per share over the next 12 months.
-
What Do Analysts Say About Q32 Bio, Inc.?
Analysts are divided on their view about Q32 Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Q32 Bio, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Q32 Bio, Inc.'s Price Target?
The price target for Q32 Bio, Inc. over the next 1-year time period is forecast to be $15.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is QTTB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Q32 Bio, Inc. is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of QTTB?
You can purchase shares of Q32 Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Q32 Bio, Inc. shares.
-
What Is The Q32 Bio, Inc. Share Price Today?
Q32 Bio, Inc. was last trading at $3.38 per share. This represents the most recent stock quote for Q32 Bio, Inc.. Yesterday, Q32 Bio, Inc. closed at $3.37 per share.
-
How To Buy Q32 Bio, Inc. Stock Online?
In order to purchase Q32 Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get QTTB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
QTTB
Sector
P/E ratio
--
24.09x
PEG ratio
--
-0.01x
P/B ratio
3.74x
1.83x
Price / LTM sales
--
1.59x
Growth Metrics
QTTB
Sector
Revenue growth
--
4.68%
Earnings growth
58.57%
10.88%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
--
-$0.18
Profitability
QTTB
Sector
Profitability FY 2024
-$487K
$3.6M
Return on invested capital
-256.32%
-31.87%
Return on assets
-52.64%
-28.18%
Return on equity
-634.27%
-37.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Jan
7
Estimated Next Earnings Date
Apr
8
Balance Sheet
QTTB
Sector
Total cash
$49M
$26.2M
Short term investments
--
$25.7M
Total assets
$92.3M
$76.7M
Long term debt
$16.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
